Copyright
©The Author(s) 2019.
World J Hepatol. Mar 27, 2019; 11(3): 294-304
Published online Mar 27, 2019. doi: 10.4254/wjh.v11.i3.294
Published online Mar 27, 2019. doi: 10.4254/wjh.v11.i3.294
Table 1 Clinicopathological parameters of the cases used for quantification of angiogenesis
Variable | Number of cases (n = 50) | Percentage |
Gender | ||
Male | 36 | 72 |
Females | 14 | 28 |
Age (mean ± SD, yr) | 64.66 ± 9.6 | |
Age groups | ||
31-50 yr | 2 | 4 |
51-60 yr | 12 | 24 |
61-70 yr | 21 | 42 |
71-80 yr | 15 | 30 |
Tumor size (mean ± SD, cm) | 40.12 ± 40.58 | |
Tumor aspect | ||
Single nodule | 36 | 72 |
Multifocality | 14 | 28 |
Tumor grade | ||
G1 | 8 | 16 |
G2 | 24 | 48 |
G3 | 17 | 34 |
G4 | 1 | 2 |
Tumor stage | ||
T1 | 23 | 46 |
T2 | 27 | 54 |
Cirrhosis | ||
Without | 32 | 64 |
With | 18 | 36 |
Mallory bodies | ||
Without | 36 | 72 |
With | 14 | 28 |
Hepatitis | ||
Without | 26 | 52 |
With | 24 | 48 |
Cholestasis | ||
Without | 41 | 82 |
With | 9 | 18 |
Steatosis | ||
Without | 33 | 66 |
With | 17 | 34 |
Table 2 Antibodies used for quantification of angiogenesis
Antibody | Clone | Company, town, country | Dilution | External control |
COX-2 | 4H12 | Novocastra, NewCastle Upon Tyne, United Kingdom | 1:100 | Brain-multipolar neurons; renal tubes |
VEGF | VG1 | LabVision, Fremont, CA, United States | 1:50 | Renal tubes |
CD31 | JC70A | DAKO,Glostrup, Denmark | 1:40 | Renal glomerules |
CD105 | SN6H | LabVision, Fremont, CA, United States | 1:50 | Tonsils |
Table 3 Assessment of COX-2 and VEGF-A expression in HCC
Parameter | COX-2 intensity | P value | VEGF-A intensity | P value | |||||
1+ | 2+ | 3+ | 1+ | 2+ | 3+ | ||||
n (%) | 14 (28) | 18 (36) | 18 (36) | 12 (24) | 28 (56) | 10 (20) | |||
Gender | |||||||||
Males | 10 | 12 | 14 | 0.75 | 8 | 22 | 6 | 0.47 | |
Females | 4 | 6 | 4 | 4 | 6 | 4 | |||
Age groups (yr) | |||||||||
31-50 | 0 | 0 | 2 | 0.47 | 0 | 1 | 1 | 0.33 | |
51-60 | 4 | 4 | 4 | 5 | 4 | 3 | |||
61-70 | 5 | 10 | 6 | 4 | 12 | 5 | |||
71-80 | 5 | 4 | 6 | 3 | 11 | 1 | |||
Tumor grade | |||||||||
G1+G2 | 13 | 7 | 12 | 0.006 | 6 | 19 | 7 | 0.50 | |
G3+G4 | 1 | 11 | 6 | 6 | 9 | 3 | |||
Tumor stage | |||||||||
pT1 | 7 | 6 | 10 | 0.38 | 3 | 12 | 8 | 0.03 | |
pT2 | 7 | 12 | 8 | 9 | 16 | 2 | |||
Associated lesions | |||||||||
With cirrhosis | 8 | 3 | 7 | 0.05 | 5 | 9 | 4 | 0.81 | |
Without cirrhosis | 6 | 15 | 11 | 7 | 19 | 6 | |||
With Mallory bodies | 7 | 5 | 2 | 0.05 | 4 | 7 | 3 | 0.85 | |
Without Mallory bodies | 7 | 13 | 16 | 8 | 21 | 7 | |||
With hepatitis | 7 | 9 | 8 | 0.93 | 6 | 14 | 4 | 0.85 | |
Without hepatitis | 7 | 9 | 10 | 6 | 14 | 6 |
Table 4 Endothelial area assessment, using CD31 and CD105 antibodies in hepatocellular carcinoma
Parameter | Number of cases | CD31-EA(median and range values) | P value | P value | |
CD105-EA(median and range values) | |||||
Gender | |||||
Males | 36 | 7.35 ± 2.16 (2.57-11.18) | 0.31 | 8.91 ± 2.64 (4.06-15.53) | 0.44 |
Females | 14 | 8.06 ± 2.30 (4.17-11.85) | 9.59 ± 3.28 (4.23-16.56) | ||
Tumor grade | |||||
G1+G2 | 32 | 7.69 ± 2.22 (2.57-11.69) | 0.53 | 9.28 ± 2.64 (4.06-16.56) | 0.55 |
G3+G4 | 18 | 7.29 ± 2.21 (3.34-11.85) | 8.78 ± 3.17 (5.77-15.53) | ||
Tumor stage | |||||
pT1 | 23 | 7.85 ± 2.33 (2.57-11.69) | 0.59 | 9.47 ± 3.15 (4.06-16.56) | 0.39 |
pT2 | 27 | 7.71 ± 2.11 (3.34-11.85) | 8.79 ± 2.51 (5.47-14.91) | ||
Associated lesions | |||||
With cirrhosis | 18 | 8.29 ± 1.68 (5.64-11.85) | 0.07 | 9.12 ± 2.51 (4.23-14.33) | 0.97 |
Without cirrhosis | 32 | 7.13 ± 2.37 (2.57-11.69) | 9.09 ± 3.01 (4.06-16.56) | ||
With Mallory bodies | 14 | 8.01 ± 1.39 (5.56-10.53) | 0.36 | 9.86 ± 2.89 (5.85-15.53) | 0.23 |
Without Mallory bodies | 36 | 7.37 ± 2.44 (2.57-11.85) | 8.81 ± 2.77 (4.06-16.56) | ||
With hepatitis | 24 | 7.28 ± 1.99 (2.57-10.53) | 0.40 | 8.26 ± 2.25 (4.23-12.28) | 0.04 |
Without hepatitis | 26 | 7.80 ± 2.39 (3.07-11.85) | 9.88 ± 3.09 (4.06-16.56) |
Table 5 Correlation of the angiogenic immunophenotype, quantified with VEGF-A and COX2, with endothelial area values
COX-2 intensity | P value | VEGF-A intensity | P value | |||||
1+ | 2+ | 3+ | 1+ | 2+ | 3+ | |||
EA-CD31 | 8.66 ± 1.41 | 7.47 ± 2.29 | 6.76 ± 2.34 | 0.04 | 7.23 ± 1.52 | 7.53 ± 2.44 | 8.01 ± 2.32 | 0.72 |
EA-CD105 | 9.22 ± 1.83 | 9.58 ± 3.56 | 8.53 ± 2.64 | 0.53 | 8.45 ± 1.74 | 8.95 ± 3.02 | 10.31 ± 3.15 | 0.28 |
- Citation: Fodor D, Jung I, Turdean S, Satala C, Gurzu S. Angiogenesis of hepatocellular carcinoma: An immunohistochemistry study. World J Hepatol 2019; 11(3): 294-304
- URL: https://www.wjgnet.com/1948-5182/full/v11/i3/294.htm
- DOI: https://dx.doi.org/10.4254/wjh.v11.i3.294